Eli Lilly ( LLY ) and Boehringer
Ingelheim recently submitted a New Drug Application (NDA) for their
type II diabetes candidate, empagliflozin, in the US. Earlier this
year, Eli Lilly and Boehringer Ingelheim had announced positive
top-line results on empagliflozin from four phase III trials.
Empagliflozin (10 and 25 mg taken once daily), a sodium glucose
co-transporter-2 (SGLT-2) inhibitor, was found to be more effective
in lowering blood sugar levels compared to placebo.
Meanwhile, the companies also announced that their marketing
authorization application (MAA) for empagliflozin has been accepted
for review by the European Medicines Agency (EMA). We note that Eli
Lilly is not the only company looking to develop a SGLT-2
inhibitor. In fact, Johnson & Johnson ( JNJ ) recently gained
FDA approval for its SGLT-2 inhibitor, Invokana.
Eli Lilly currently carries a Zacks Rank #2 (Buy). We are
pleased with the company's efforts to strengthen its diabetes
franchise. Eli Lilly's diabetes franchise consists of products like
Humulin, Humalog, and Tradjenta among others.
Last month, Eli Lilly and Boehringer Ingelheim had announced the
commencement of a phase IIIb study with Tradjenta in type II
diabetes patients with prevalent albuminuria who are currently
receiving standard treatment for diabetic nephropathy.
The 24-week, multicenter, multinational, randomized,
double-blind, placebo-controlled, parallel-group study, MARINA
(efficacy, safety & Modification of Albuminuria in type 2
diabetes subjects with Renal disease with LINAgliptin), will
evaluate the glycemic efficacy and safety of once-daily Tradjenta
(5 mg). The study is slated to complete in 2014.
Currently, Novo Nordisk ( NVO ) also looks
well-positioned in the pharma sector with a Zacks Rank #2.
Abbott Labs ( ABT ) is another
company that currently holds a Zacks Rank #2.ABBOTT LABS (ABT): Free Stock Analysis ReportJOHNSON & JOHNS (JNJ): Free Stock Analysis
ReportLILLY ELI & CO (LLY): Free Stock Analysis
ReportNOVO-NORDISK AS (NVO): Free Stock Analysis
ReportTo read this article on Zacks.com click here.Zacks Investment